Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Nyxoah S.A.NASDAQ: NYXH
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of €727.75K (cash outflow) rose 246.5% year over year, ahead of the -65.8% change in trailing-twelve-month capital expenditures. Sequentially, it rose 3367.0% from the prior quarter. Over 3 fiscal years it compounded at -63.4% a year.
Context
- Capital expenditures amounted to 8.0% of revenue in FY2025, down 126.3 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +246.5% holds above the trailing-twelve-month pace of -65.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
EUR · from the cash flow
- Latest · FY2025
- (804.7K) EUR
- Year-over-year change
- +86.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (804.7K) | +86.7% |
| FY2024 | 2024-12-31 | (6.07M) | +44.6% |
| FY2023 | 2023-12-31 | (10.96M) | +33.0% |
| FY2022 | 2022-12-31 | (16.35M) | -38.4% |
| FY2021 | 2021-12-31 | (11.82M) | — |
Capital Expenditures vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -65.8% is the 8th highest of 9, against a peer median of -46.9%.
- Capital expenditures amounts to 8.1% of revenue for NYXH, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.95M USD | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $4.69M USD | +77.8% | -96.0% | 4.1% | |
| LTM Mar 2026 | €1.32M EUR | -65.8% | -63.4% | 8.1% | |
| LTM Mar 2026 | $779K USD | -40.5% | -37.4% | 0.5% | |
| LTM Mar 2026 | $737K USD | +411.8% | -55.0% | 1.3% | |
| LTM Mar 2026 | $578.97K USD | -64.0% | -30.7% | 1.3% | |
| LTM Mar 2026 | $523K USD | -54.8% | -68.0% | 1.8% | |
| LTM Mar 2026 | $317K USD | +85.4% | -23.2% | 0.8% | |
| LTM Mar 2026 | $208K USD | — | -68.0% | 0.2% | |
| LTM Mar 2026 | $50K USD | -53.3% | -7.8% | — | |
| Peer median (excluding NYXH) | — | -46.9% | -37.4% | 1.3% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (90.05M) |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 2.72M | 4.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.27M | 2.7M | 2.61M | 3.97M | 0 |
| Change in Working Capital | (1.14M) | 86K | (3.49M) | 2.96M | 5.37M |
| Accounts Receivables | (2.52M) | 7K | (1.54M) | (751K) | (2.14M) |
| Inventory | (291K) | (536K) | (2.43M) | (1.4M) | 55.98K |
| Accounts Payables | 0 | 0 | 0 | 0 | 7.45M |
| Other Working Capital | 1.67M | 615K | 479K | 5.11M | 0 |
| Other Non-Cash Items | (2.49M) | (3.42M) | (1.6M) | (2.44M) | 12.7M |
| Operating Cash Flow | (25.34M) | (28.76M) | (44.78M) | (49.23M) | (67.5M) |
| Capital Expenditures | (11.82M) | (16.35M) | (10.96M) | (6.07M) | (804.7K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | (102.62M) | (80.02M) | (97.83M) | (42.03M) |
| Sales of Investments | 0 | 28.91M | 120.68M | 85.31M | 71.97M |
| Other Investing Activities | (10.35M) | (15.35M) | (6.15M) | (2.64M) | 0 |
| Investing Cash Flow | (11.82M) | (89.95M) | 32.01M | (16.33M) | 26.17M |
| Debt Repayment | (863K) | (1.07M) | (1.24M) | 8.48M | 21.19M |
| Common Stock Issued | 77.73M | 255K | 18.34M | 69.72M | 20.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (393K) | (167K) | (243K) | (758K) | (3.26M) |
| Financing Cash Flow | 76.47M | (983K) | 16.86M | 77.44M | 38.79M |
| Effect of Forex Changes | 3.89M | 2.06M | (369K) | 688K | 2.41M |
| Net Change in Cash | 43.21M | (117.62M) | 3.72M | 12.58M | (130.69K) |
| Free Cash Flow | (37.15M) | (45.11M) | (55.74M) | (55.3M) | (68.3M) |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.